Article in Journal of bone oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 2 institutions in 1 country.
Francesca FontanaDivision of Bone and Mineral Diseases, Musculoskeletal Research Center, United States.
Jingyu XiangDivision of Molecular Oncology, Department of Medicine, United States.
Xinming SuDivision of Molecular Oncology, Department of Medicine, United States.
Eric TycksenGenome Technology Access Center, Washington University School of Medicine, St. Louis, MO, United States.
Rachel NassauDivision of Bone and Mineral Diseases, Musculoskeletal Research Center, United States.
Gregory FoxDivision of Molecular Oncology, Department of Medicine, United States.
Giulia LeanzaDivision of Bone and Mineral Diseases, Musculoskeletal Research Center, United States.
Katherine WeilbaecherDivision of Molecular Oncology, Department of Medicine, United States.
Roberto CivitelliDivision of Bone and Mineral Diseases, Musculoskeletal Research Center, United States.
Molecular Oncology (United States) · USWashington University in St. Louis · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Role of Inflammation in Tax-mediated TumorigenesisP01CA100730 · NCI · WASHINGTON UNIVERSITY · PI Lee Ratner · 2003 to 2026
$44.8M
Resource Based Center for Musculoskeletal Biology and Medicine (Overall Application)P30AR074992 · NIAMS · WASHINGTON UNIVERSITY · PI MATTHEW J SILVA · 2019 to 2026
$6.8M
The Role of the Osteoblast Secretome in Bone FormationP30AR057235 · NIAMS · WASHINGTON UNIVERSITY · PI SILVA, MATTHEW J · 2009 to 2018
$5.7M
Skeletal Disorders Training ProgramT32AR060719 · NIAMS · WASHINGTON UNIVERSITY · PI Roberto Civitelli · 2011 to 2026
$4.6M
ROLE OF BETA 3 INTEGRIN IN SKELETAL METASTASISR01CA097250 · NCI · WASHINGTON UNIVERSITY · PI WEILBAECHER, KATHERINE NELSON · 2003 to 2014
$3.3M
NEXT GENERATION APPROACHES TO BREAST CANCER USING IMAGE GUIDED DRUG DELIVERYR01CA154737 · NCI · WASHINGTON UNIVERSITY · PI LANZA, GREGORY M, PAN, DIPANJAN · 2011 to 2015
$2.4M
N-cadherin in Extraskeletal Osteolineage Cells Modulates Tumor GrowthR01CA243383 · NCI · WASHINGTON UNIVERSITY · PI CIVITELLI, ROBERTO · 2020 to 2024
$1.9M
ROLE OF BETA 3 INTEGRIN IN SKELETAL METASTASISR56CA097250 · NCI · WASHINGTON UNIVERSITY · PI WEILBAECHER, KATHERINE NELSON · 2009 to 2009
Tumor growth and metastases are dependent on interactions between cancer cells and the local environment. Expression of the cell-cell adhesion molecule N-cadherin (Ncad) is associated with highly aggressive cancers, and its expression by osteogenic cells has been proposed to provide a molecular "dock" for disseminated tumor cells to establish in pre-metastatic niches within the bone. To test this biologic model, we conditionally deleted the Ncad gene (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
N-cadherin in osteolineage cells modulates stromal support of tumor growth. · full record | OpenQuestion